Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May:138:104784.
doi: 10.1016/j.nbd.2020.104784. Epub 2020 Feb 4.

APOE-amyloid interaction: Therapeutic targets

Thomas Wisniewski  1 , Eleanor Drummond  2
Affiliations
Review

APOE-amyloid interaction: Therapeutic targets

Thomas Wisniewski et al. Neurobiol Dis. 2020 May.

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that is growing in prevalence globally. It is the only major cause of death without any effective pharmacological means to treat or slow progression. Inheritance of the ε4 allele of the Apolipoprotein (APO) E gene is the strongest genetic risk factor for late-onset AD. The interaction between APOE and amyloid β (Aβ) plays a key role in AD pathogenesis. The APOE-Aβ interaction regulates Aβ aggregation and clearance and therefore directly influences the development of amyloid plaques, congophilic amyloid angiopathy and subsequent tau related pathology. Relatively few AD therapeutic approaches have directly targeted the APOE-Aβ interaction thus far. Here we review the critical role of APOE in the pathogenesis of AD and some of the most promising therapeutic approaches that focus on the APOE-Aβ interaction.

Keywords: Apolipoprotein E; Beta amyloid; Early onset AD; Immunomodulation; Interaction; Oligomers; Pathological chaperone; Peptoids; Therapy.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Illustration of the potential effects of blocking the APOE-Aβ interaction with resultant reduction of the major pathologies that characterize AD.
See this image and copyright information in PMC

References

    1. Alzheimer’s Association, 2019. 2019 Alzheimer’s disease facts and figures. AlzheimersDement 15 (3), 321–387.
    1. Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C,Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, Leyton-Cifuentes D, Chen K, Baena A, Aguillon D, Rios-Romenets S, Giraldo M, Guzmán-Vélez E, Norton DJ, Pardilla-Delgado E, Artola A, Sanchez JS, Acosta-Uribe J, Lalli M, Kosik KS, Huentelman MJ, Zetterberg H, Blennow K, Reiman RA, Luo J, Chen Y, Thiyyagura P, Su Y, Jun GR, Naymik M, Gai X, Bootwalla M, Ji J, Shen L, Miller JB, Kim LA, Tariot PN, Johnson KA, Reiman EM, Quiroz YT, 2019. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med 10.1038/s41591-019-0611-3. in press. - DOI - PMC - PubMed
    1. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM, 2009. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci 29 (21), 6771–6779. - PMC - PubMed
    1. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P,Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM, 1997. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat.Gen 17 (3), 263–264. - PubMed
    1. Banik A, Brown RE, Bamburg J, Lahiri DK, Khurana D, Friedland RP, Chen W,Ding Y, Mudher A, Padjen AL, Mukaetova-Ladinska E, Ihara M, Srivastava S, Padma Srivastava MV, Masters CL, Kalaria RN, Anand A, 2015. Translation of pre-clinical studies into successful clinical trials for Alzheimer’s disease: what are the roadblocks and how can they be overcome? J. Alzheimers Dis 47 (4), 815–843. 10.3233/JAD-150136. - DOI - PubMed

Publication types